Use of ARTRA MSM FORTE in patients with knee osteoarthritis: Results of a randomized open-label comparative study of the efficacy and tolerability of the drug


Cite item

Full Text

Abstract

Aim. To study the clinical efficacy and safety of the combined medication ARTRA MSM FORTE (400 mg chondroitin sulfate, 500 mg glucosamine hydrochloride, 300 mg methylsulfonylmethane (MSM), and 10 mg sodium hyaluronate calculated with reference to hyaluronic acid) in patients with knee osteoarthritis (OA). Subjects and methods. The study enrolled 100 patients with Kellgren-Lawrence grades 2—3 knee OA with obvious pain syndrome (pain intensity scores on a visual analog scale (VAS)) equal or greater than 40 mm during walking. The patients were examined monthly; changes in WOMAC index scores, Get-Up and Go test results, the efficiency of therapy in the opinion of a physician and a patient, and quality of life according to the EQ-5D questionnaire were estimated. They were randomized into 2 groups: 1) 50 patients took ARTRA MSM as 2 tablets daily for one month, then 1 tablet daily; 2) 50 received ARTRA in accordance with the same scheme. Clinical examination was performed before and at 30, 60, 90 and 120 days of the study. Results. All the 100 patients completed treatment. Analysis of the results showed a significant decrease in pain on VAS in both groups. Reduced pain intensity was observed by the end of the first month of therapy and remained throughout the follow-up. Both medications diminished stiffness just after a month of therapy. They alleviated joint function and reduced total WOMAC scores at Visit 2. Analysis of Get-Up and Go test results indicated significantly less spent time in both groups; however, these differences reached the statistical significance in the ARTRA MSM group just at Visit 2 and in the ARTRA group only at Visit 3. The effect ARTRA MSM occurred more rapidly. This was confirmed by the patient and physician evaluations of the efficiency of treatment, which indicated that its positive effect occurred more rapidly in the ARTRA MSM group (p=0.02). Estimation of EQ-5D scores also showed positive results: there was a significant improvement of these indicators in the two compared groups at Visit 3. Both medications were very well tolerated and caused no adverse reactions; therapy was not discontinued. Conclusion. ARTRA MSM is rapider in its effect: a significant improvement in Get-Up and Go test results and patient and physician evaluations of the efficiency of treatment. Additional interviews of the patients taking ARTRA MSM demonstrated that 36 (72%) of them reported a prompter pain relief than the ARTRA-treated patients. ARTRA MSM may be recommended for the treatment of OA in clinical practice.

References

  1. McAlindon T, Bannuru R, Sullivan M, Arden N, Berenbaum F, Bierma-Zeinstra S, Hawker G, Henrotin Y, Hunter D, Kawaguch, H, Kwoh K, Lohmander S, Rannou F, Roos E, Underwood M. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-388. doi: 10.1016/j.joca.2015.02.014.
  2. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas 2014;78:184-187. doi: 10.1016/j.maturitas.2014.07.018.
  3. Bruyère O, Cooper C, Pelletier J, Branco J, Brandi LM, Guillemin F, Hochberg MC, Kanis JA, Kvien TK, Martel-Pelletier J, Rizzoli R, Silverman S, Reginster J. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014:2-11. doi: 10.1016/j.semarthrit.2014.05.014.
  4. Hochberg M, Martel-Pelletier J, Monfort J, Moller I, Castillo JR, Arden N, Berenbaum F, Conaghan P, Pap T, Richette P, Sawitzke A, du Souich P, Pelletier JP. The Multicentric Osteoarthritis interVEntion Study with Sysadoa (MOVES). MOVES Steering Committee. Osteoarthritis and Cartilage. 2014;22:S7-S56. doi: 10.1136/annrheumdis-2014-eular.4950.
  5. Fransen M, Agaliotis M, Nairn L, Votrubec M, Bridgett L, Su S, Jan S, March L, Edmonds J, Norton R, Woodward M, Day R. Glucosamine and chondroitin for knee placebo- controlled clinical trial evaluating osteoarthritis: a double-blind randomized single and combination regimens. Ann Rheum Dis. 2014;0:1-8. doi: 10.1136/annrheumdis-2013-20395.
  6. Martel-Pelletier J, RoubilleC, AbramF, Hochberg MC et al. Data from the osteoarthritis initiative progression cohort Published Online First 13 December 2013. doi: 10.1107/s1600536806054936.
  7. Alekseeva L, Chichasova N, Mendel O. Rational choice of basic therapy in osteoarthritis. The results of a multicenter, randomized, open study ARTRA in Russia. RMJ 2005;24(248):1637-1640.
  8. Kocsis JJ, Harkaway S, Snyder R. Biological effects of the metabolites of dimethyl sulfoxide. Ann New York Academy of Sciences. 1975;243:104-109. doi: 10.1111/j.1749-6632.1975.tb25349.x.
  9. Hucker HB, Miller JK, Hochberg A, Brobyn RD, Riordan FH, Calesnick B. Studies on the absorption, excretion and metabolism of dimethylsulfoxide (DMSO) in man. J Pharmacol Exper Ther. 1967;155:309-317.
  10. Engelke UF, Tangerman A, Willemsen MA, Moskau D, Loss S, Mudd SH, Wevers RA. Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by onedimensional (1) H and two-dimensional (1)H-(13)C NMR. J Radiol Nucl Med. 2005; 18:331-336. doi: 10.1002/nbm.966.
  11. Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. Anticancer Res. 2003;23:453-458.
  12. Alam SS, Layman DL. Dimethyl sulfoxide inhibition of prostacyclin production in cultured aortic endothelial cells. Ann New York Academy Scie. 1983;411:318-320. doi: 10.1111/j.1749-6632.1983.tb47314.x.
  13. Beilke MA, Collins-Lech C, Sohnle PG. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med. 1987;110:91-96.
  14. Morton J, Moore R. Lupus nephritis and deaths are diminished in B/W mice drinking 3% water solutions of dimethyl sulfoxide (DMSO) or dimethyl sulfone (DMSO2). J Leukocyte Biol. 1986; 40:322.
  15. Hasegawa T. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japanese Pharmacol Ther. 2004;32:421-427.
  16. Usha P, Naidu M. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Investigat. 2004;24:353-363. doi: 10.2165/00044011-200424060-00005.
  17. Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. OsteoArthritis and Cartilage. 2006;14:286-294. doi: 10.1016/j.joca.2005.10.003.
  18. Pagonis TA, Givissis PK, Kritis AC, Christodoulou AC. The Effect of Methylsulfonylmethane on Osteoarthritic Large Joints and Mobility. Int J Orthopaed. 2014;1(1):19-24. doi:http://dx.doi.org/10.1016/j.injury.2011.03.018.
  19. Sudha Vidyasagar, Prabhu Mukhyaprana, U. Shashikiran, Adiga Sachidananda, Sharath Rao, K. Laxminarayana Bairy, Shalini Adiga and B. Jayaprakash. Efficacy and Tolerability of Glucosamine Chondroitin Sulphate — Methyl Sulfonyl Methane (MSM) in Osteoarthritis of Knee in Indian Patients. Int J Pharm Technol. 2004;3:61-65.

Copyright (c) 2015 Alekseeva L.I., Sharapova E.P., Kashevarova N.G., Taskina E.A., Anikin S.G., Korotkova T.A., Pyanykh S.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies